Autores
Kim N Chi, Andrew Protheroe, Alfredo Rodríguez-Antolín, Gaetano Facchini, Henrik Suttman, Nobuaki Matsubara, Zhangqun Ye, Bhumsuk Keam, Ronaldo Damião, Tracy Li, Kelly McQuarrie, Bin Jia, Peter De Porre, Jason Martin, Mary B Todd, Karim Fizazi
Fecha de publicación
2018/2/1
Revista
The Lancet Oncology
Volumen
19
Número
2
Páginas
194-206
Editor
Elsevier
Descripción
Background
In the LATITUDE trial, addition of abiraterone acetate plus prednisone to androgen deprivation therapy (ADT) improved overall survival compared with placebos plus ADT in patients with newly diagnosed, high-risk, metastatic castration-naive prostate cancer. Understanding the effects of treatments on patient-reported outcomes (PROs) and health-related quality of life (HRQOL) is important for treatment decisions; therefore we aimed to analyse the effects of ADT plus abiraterone acetate and prednisone versus ADT plus placebos on PROs and HRQOL in patients in the LATITUDE study.
Methods
In the multicentre, international, randomised, phase 3 LATITUDE trial, eligible patients were aged 18 years or older, had newly diagnosed, high-risk, metastatic castration-naive prostate cancer confirmed by bone scan (bone metastases) or by CT or MRI (visceral, soft tissue, or nodal metastases), and an Eastern …
Citas totales
Artículos de Google Académico
KN Chi, A Protheroe, A Rodríguez-Antolín, G Facchini… - The Lancet Oncology, 2018
